Advisory Services Network LLC Has $836,000 Stock Holdings in Organon & Co. (NYSE:OGN)

Advisory Services Network LLC lifted its position in shares of Organon & Co. (NYSE:OGNFree Report) by 4.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,962 shares of the company’s stock after buying an additional 2,204 shares during the quarter. Advisory Services Network LLC’s holdings in Organon & Co. were worth $836,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of OGN. Nordea Investment Management AB grew its position in shares of Organon & Co. by 2,016.0% during the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock worth $44,648,000 after purchasing an additional 2,980,945 shares in the last quarter. Invesco Ltd. grew its position in Organon & Co. by 23.7% during the third quarter. Invesco Ltd. now owns 10,240,630 shares of the company’s stock worth $177,777,000 after buying an additional 1,963,682 shares in the last quarter. Norges Bank bought a new position in Organon & Co. during the 4th quarter worth $26,321,000. Sound Shore Management Inc. CT increased its stake in Organon & Co. by 35.2% during the 4th quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock worth $67,415,000 after acquiring an additional 1,216,522 shares during the period. Finally, Private Management Group Inc. raised its holdings in Organon & Co. by 78.5% in the 4th quarter. Private Management Group Inc. now owns 2,335,238 shares of the company’s stock valued at $33,674,000 after acquiring an additional 1,027,276 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. The Goldman Sachs Group increased their target price on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Piper Sandler lifted their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, April 29th.

Read Our Latest Research Report on OGN

Organon & Co. Stock Performance

NYSE:OGN opened at $21.33 on Friday. The stock’s 50-day moving average is $19.44 and its 200-day moving average is $16.73. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $24.08. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35. The stock has a market cap of $5.49 billion, a P/E ratio of 5.22, a price-to-earnings-growth ratio of 0.91 and a beta of 0.81.

Organon & Co. (NYSE:OGNGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.83 by $0.31. Organon & Co. had a net margin of 16.50% and a negative return on equity of 360.57%. The business had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Equities research analysts anticipate that Organon & Co. will post 4.3 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be issued a $0.28 dividend. The ex-dividend date is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a yield of 5.25%. Organon & Co.’s payout ratio is 27.38%.

Organon & Co. Profile

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

See Also

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with's FREE daily email newsletter.